{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:40:17Z","timestamp":1765294817985},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7132091"],"award-info":[{"award-number":["7132091"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Municipal Science and Technology Commission Funds","award":["Z121107001012138"],"award-info":[{"award-number":["Z121107001012138"]}]},{"name":"Capital Health Research and Development Project","award":["2011-2002-02"],"award-info":[{"award-number":["2011-2002-02"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejphar.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T05:02:41Z","timestamp":1468126961000},"page":"127-133","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial"],"prefix":"10.1016","volume":"789","author":[{"given":"Dongliang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoxin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LiYan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.07.019_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bone.2007.10.003","article-title":"Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake","volume":"42","author":"Adami","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2016.07.019_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","article-title":"Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD","volume":"50","author":"Al-Aly","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2016.07.019_bib3","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1210\/jc.2004-0360","article-title":"Vitamin D2 is much less effective than vitamin D3 in humans","volume":"89","author":"Armas","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.07.019_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.jrn.2008.04.008","article-title":"Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (Vitamin D2) in stage 5 chronic kidney disease patients","volume":"18","author":"Blair","year":"2008","journal-title":"J. Ren. Nutr."},{"key":"10.1016\/j.ejphar.2016.07.019_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ndt\/gfi186","article-title":"The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells","volume":"21","author":"Brown","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2016.07.019_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5301\/jn.5000123","article-title":"Vitamin D2 versus vitamin D3 supplementation in hemodialysis patients: a comparative pilot study","volume":"26","author":"Daroux","year":"2013","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1440-1797.2006.00698.x","article-title":"Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease","volume":"11","author":"DeVille","year":"2006","journal-title":"Nephrology"},{"key":"10.1016\/j.ejphar.2016.07.019_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/00365513.2012.744464","article-title":"Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5","volume":"73","author":"Gravesen","year":"2013","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"10.1016\/j.ejphar.2016.07.019_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/jc.2007-2308","article-title":"VitaminD2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D","volume":"93","author":"Holick","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.07.019_bib10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.2215\/CJN.02160309","article-title":"Vitamin D and parathyroid hormone in general populations: understandings in 2009 and applications to chronic kidney disease","volume":"4","author":"Johal","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib11","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2009","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ejphar.2016.07.019_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2011.06.027","article-title":"Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial","volume":"59","author":"Kovesdy","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2016.07.019_bib13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","article-title":"Prevalence of calcidiol deficiency in CKD: a crosssectional study across latitudes in the United States","volume":"45","author":"LaClair","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2016.07.019_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2016.07.019_bib15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1373\/clinchem.2005.052936","article-title":"Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3","volume":"51","author":"Maunsell","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2016.07.019_bib16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2215\/CJN.05781207","article-title":"Hypovitaminosis D in chronic kidney disease","volume":"3","author":"Mehrotra","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.07131009","article-title":"A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease","volume":"5","author":"Moe","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bonemetabolismand disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2016.07.019_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2369-15-47","article-title":"Vitamin D resistance in chronic kidney disease (CKD)","volume":"15","author":"Parikh","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/0886022X.2011.553303","article-title":"Vitamin D status and mortality risk in patients with chronic kidney disease","volume":"33","author":"Santoro","year":"2011","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ejphar.2016.07.019_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.5301\/jn.5000203","article-title":"Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients","volume":"26","author":"Santoro","year":"2013","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00467-010-1691-y","article-title":"Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?","volume":"26","author":"Shroff","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1681\/ASN.2007090993","article-title":"A bimodal association of vitamin D levels and vascular disease in children on dialysis","volume":"19","author":"Shroff","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2215\/CJN.04760511","article-title":"Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial","volume":"7","author":"Shroff","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib25","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1681\/ASN.2006121397","article-title":"Mineral metabolism and vascular damage in children on dialysis","volume":"18","author":"Shroff","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2016.07.019_bib26","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1001\/jama.294.18.2336","article-title":"Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake","volume":"294","author":"Steingrimsdottir","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2016.07.019_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.bone.2008.11.016","article-title":"Serum 25-hydroxyvitamin D as an independent determinant of 1\u201384 PTH and bone mineral density in nondiabetic predialysis CKD patients","volume":"44","author":"Tomida","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2016.07.019_bib28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2016.07.019_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00223-013-9811-x","article-title":"Is the dialysis calcium concentration of 1.75 mmlo\/L suitable for Chinese patients on maintenance hemodialysis?","volume":"94","author":"Zhang","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ejphar.2016.07.019_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease","volume":"27","author":"Zisman","year":"2007","journal-title":"Am. J. Nephrol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916304496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916304496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T16:23:25Z","timestamp":1536596605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916304496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":30,"alternative-id":["S0014299916304496"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.019","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}